Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

POS0220 INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS

(2021) S. B. Cohen et al.   ANNALS OF THE RHEUMATIC DISEASES

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

(2021) Emma Guttman-Yassky et al.   LANCET

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

(2021) Brian G Feagan et al.   LANCET

S777 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials

(2021) William Sandborn et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

(2021) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

(2020) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

(2020) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial

(2020) Ronald van Vollenhoven et al.   Arthritis & Rheumatology

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

(2020) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

ACG Clinical Guideline

(2019) David T. Rubin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

(2019) Josef S Smolen et al.   LANCET

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

(2019) Silvio Danese et al.   GUT

Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols

(2019) Sebastian Häckl et al.   PHARMACEUTICAL STATISTICS

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Approach to cytomegalovirus infections in patients with ulcerative colitis

(2017) Sung Chul Park et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

(2015) Axel U Dignass et al.   Journal of Crohns & Colitis

Update on Janus Kinase Antagonists in Inflammatory Bowel Disease

(2014) Brigid S. Boland et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Abdominal Pain in Ulcerative Colitis

(2013) Matthew D. Coates et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY